Purin-Ago: Non-nucleotide agonists of the P2Y11-receptor with immunosuppressant effect
Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide
agonists of the P2Y11-receptor. The agonists ensure high specificity among P2-receptors which is a key to tolerability of compounds meant for applications in longterm treatment settings. Activation of the P2Y11-receptor leads to a variety of effects in the modulation of immune system activity. For example release of immune modulatory thrombospondin-1 is induced, while lipopolysaccharide (LPS)-stimulated release of the pro-inflammatory cytokine interleukin-12 (IL- 12) is inhibited by activation of the P2Y11-receptor.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Retinoblastoma: Eye-Catching Investigation into Retinal Tumor Cells
A research team from the Medical Faculty of the University of Duisburg-Essen and the University Hospital Essen has developed a new cell culture model that can be used to better…
A Job Well Done: How Hiroshima’s Groundwater Strategy Helped Manage Floods
Groundwater and multilevel cooperation in recovery efforts mitigated water crisis after flooding. Converting Disasters into Opportunities Society is often vulnerable to disasters, but how humans manage during and after can…
Shaping the Future: DNA Nanorobots That Can Modify Synthetic Cells
Scientists at the University of Stuttgart have succeeded in controlling the structure and function of biological membranes with the help of “DNA origami”. The system they developed may facilitate the…